Meeting
2014 ASCO Annual Meeting
Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma.
Authors
Steven G. DuBois
University of California, San Francisco, San Francisco, CA
Steven G. DuBois , M. Shelly Allen , Melissa Bent , Joan Hilton , Fabienne Hollinger , Jesse Courtier , Randall Hawkins , Yael P. Mosse , Katherine K. Matthay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01313936
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10033)
DOI
10.1200/jco.2014.32.15_suppl.10033
Abstract #
10033
Poster Bd #
334
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for relapsed or refractory neuroblastoma: A report from the NANT Consortium.
First Author: Kevin M. Campbell
Poster
2022 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.
First Author: Shakeel Modak
Poster
2016 ASCO Annual Meeting
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
First Author: Steven G. DuBois
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu